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Different interpretations have been provided by Perrella 
et al. [I] to explain the expansion of TCS-Fl+/A13+ 
cells in the peripheral blood, including selective stimu- 
lation of Vsl subset by I? curinii and/or involvement of 
this subset in early host defence against the opportunistic 
infection. The increase of the V Q +  cells observed in 
the lung, i.e., the microenvironment where the immune 
response against I? curinii takes place, strongly suggests the 
alternative hypothesis that target antigens (including F! 
curinii antigens) and/or environmental stimuli may favour 
the expansion of the circulating T C R  y/6 cell pool 
and the later selective migration of Vs2+/BB3+ cells 
&om the peripheral blood to the lung. In this scenario, 
the depletion of BB3+ cells in the peripheral blood 
(and the consequent increase in the relative percentage 
of AlS+/Vsl+ cells) is likely to represent an epiphe- 
nomenon, related to the redistribution of V82+ cells to 
the sites of PCP-associated inflammation. Further studies 
are also needed to determine whether HIV infection of 
pulmonary cells (including alveolar macrophages, pul- 
monary lymphocytes and fibroblasts) [6] may represent 
an additional factor accounting for the selective local 
expansion of Vg2+ cells. 
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Zidovudine to decrease mother-to-child transmission of HIV-1: is it good for developing countries? 
The results of the intermediate analysis of the AIDS 
Clinical Trials Group (ACTG) 076/Agence Nationale 
de Recherches sur le SIDA (ANRS) 024 clinical trial 
conducted in the USA and France have demonstrated 
the efficacy of zidovudine (ZDV) in reducing the rate of 
mother-to-child transmission (MTCT) of HIV-1. These 
findings have already begun to transform clinical practice 
in industrialized countries, despite the lack of long-term 
safety data [l]. Afiica has the highest incidence of peri- 
natally acquired AIDS [2], but other areas of high inci- 
dence/prevalence already exist in developing countries 
such as Thailand. Decreasing M T C T  of HIV-1 must be 
a public-health priority in this context. 
If ZDV can be considered as the gold standard for re- 
ducing vertical 'transmission in the industrialized world, 
is it time to shift priorities throughout the world? In 
pursuing such a goal, it is necessary to face not only 
the critical problem of cost to individuals and health-care 
systems, but also the uncertainties about the applicability, 
tolerance, and even the efficacy of prescriptions derived 
fiom the ACTG 076 protocol [3]. 
The efficacy of ZDV has been demonstrated only under 
specific conditions: 100mg oral doses five times daily 
beginning between 14 and 34 weeks of gestation, in- 
travenous infusion during labour and delivery, and ad- 
ministration of ZDV syrup to the neonate four times 
daily beginning within 24 h ofbirth for 6 weeks. Leaving 
aside the cost, this protocol is clearly inapplicable in most 
developing countries. First, it requires that HIV testing, 
with pre- and post-test counselling, be performed early 
in pregnancy. Second, the acceptability of medications 
to be taken several times daily by mother and neonate 
may often be poor. Third, intravenous infusions during 
labour/delivery require admission early in labour and 
the management of intravenous lines may be ineffective, 
if not dangerous, in maternities lacking trained person- 
nel and sterile conditions. Finally, whereas the ACTG 
076 trial was conducted in a non-breastfeeding popula- 
tion, the relevance of these results may be quite different 
where infants are breastfed [4]. 
We therefore suggest that ZDV be introduced in de- 
veloping countries to decrease MTCT of HIV-1 only 
if relatively widely applicable protocols are constructed, 
evaluated and proven to be effective. Among others, the 
following options may be proposed (Table l), alone or in 
combination, considering that late in utero and intrapar- 
tum HIV transmissions are thought to be predominant in 
the timing of acquisition of the infection by the future 
child [5,6]: oral ZDV at the end of pregnancy, with a 
. 
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simplified daily schedule; an oral loading dose during 
labour/delivery; syrup to the neonate; oral ZDV to the 
mother during some or all the breastfeeding period. 
Attempts must be made to apply ZDV to reducing 
postnatal transmission in a context where breastfeed- 
ing will not usually be withheld. The proven benefits 
of breast milk on perinatal morbidity and mortality are 
widely thought to outweigh the potential risk of HIV 
transmission in developing countries, leading the World 
Health Organization (WHO) and the United Nations 
Children’s Fund (UNICEF) to recommend breastfeed- 
ing regardless of the maternal HIV infection status [7]. 
If maternal ZDV therapy is to be given throughout the 
breastfeeding period, it should be prolonged at least 4-6 
months, which is the period recommended by UNICEF 
for exclusive breastfeeding in its recent Baby-Friendly 
Initiative [SI. O n  the other hand, there is legitimate con- 
cern that postnatal transmission occurring despite ma- 
ternal ZDV treatment and/or following the end of the 
therapy may cancel the benefit of decreasing in utero 
and/or intrapartum transmission. The ethical and prac- 
tical aspects of the controversy over breastfeeding will be 
I 
correctly addressed only when the actual contribution of 
breastfeeding to MTCT of HIV-1 is quantified. 
Regardless of the protocol chosen, clinical trials must 
evaluate not only the efficacy but also the tolerance 
of ZDV in developing countries. Adverse effects may 
be different and more frequent than in France and the 
United States; for example, the prevalence of severe 
anaemia is high in African pregnant women [9]. Well- 
designed Phase II tolerance studies should therefore be 
a necessary step in evaluating ZDV in developing coun- 
tries. 
In designing clinical trials of ZDV in developing coun- 
tries, one must answer several diffcult ethical questions. 
The first is whether the drug can be available afterwards 
outside of a clinical trial setting [lo]. The main obstacle 
is cost, which calls for effective negotiations between the 
public-health authorities of the concerned states, bilat- 
eral and international agencies such as WHO, and phar- 
maceutical companies. Another diffcult ethical problem 
is whether to perform a placebo-controlled trial. Panels 
of experts convened by the ANRS in France and WHO 
in March and June 1994 stressed that placebo-controlled 
Table 1. Comparative advantages and disadvantages of proposed regimens for zidovudine (ZDV) administration to reduce mother-to-child transmission 
of HIV-1 in developing countries. 
Advantages Drawbacks 
All regimens 
ACTC 076 protocol 
Oral ZDV during late 
third trimester 
Intravenous infusion of ZDV 
in labour 
Efficacy of ZDV suggested 
by ACTG 076 data 
Efficacy in USA-France 
Most easily acceptable 
Cost less than ACTC 076 
Applicable when testing 
in third trimester 
Maximum concentration 
Low cost 
intrapartum 
Oral ZDV booster in labour Acceptable 
Low cost 
, 
Long-term effects unknown 
Adverse effects in women and neonates 
(e.g., anaemia) unknown 
No data on women with <200~106/1 CD4 lymphocytes 
Effects on postnatal transmission unknown 
cost 
Requires trained personnel 
Compliance difficult 
Highest cost 
Requires second trimester HIV testing 
No impact on early in utero transmission 
Effect on intrapartum transmission unknown 
No expected effect on postnatal transmission 
but potentially limited 
B 
Inapplicable in most labour wards where 
admission occurs in advanced labour 
Requires sterile material and trained personnel 
Intrapartum plasma ZDV concentration possibly 
lower than with intravenous infusion 
ZDV syrup to neonate Possible effect on early Efficacy of post-exposure prophylaxis questionable 
No effect on late postnatal transmission 
Adverse effects unknown in children 
Confront with alternatives to breastfeeding 
Pharmacokinetics of ZDV excretion in colostrumlmilk 
Confront with alternatives to breastfeeding 
postnatal transmission 
Oral ZDV to mother Possible effect on postnatal 
Adverse effects in neonate 
after delivery transmission poorly studied 1 
lesser than for s 
$ 
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trials offer the best option for a rapid and scientifically 
valid assessment of antiretroviral drug regimens to reduce 
MTCT of HIT? 
ZDV may not be at present the ideal means to decrease 
MTCT of HIV-1 in developing countries. Non-nucle- 
oside antiretroviral drugs such as nevirapine may also act 
by reducing the maternal viral load for a short period 
of time and active/passive immunizations are other po- 
tential approaches [ll]. Less costly, more accessible al- 
ternatives should also be considered. Local disinfection 
during late pregnancy and labour may be of benefit to 
decrease HIV transmission by the ascending route and 
during delivery itself[12]. Ifsuch an intervention were to 
be effective and well tolerated, it could be widely applied 
even in settings where HIV testing is not available. 
The results of the ACTG 076 trial must encourage re- 
searchers in developing countries to design and imple- 
ment trials to determine the tolerance and efficacy of 
ZDV and other drug strategies that are likely to be 
widely applicable in the future. Prospects for an effective 
intervention should also incite public-health authorities 
to make prenatal HIV testing available. The international 
health community has a specific responsibility towards 
reducing the price of antiretrovirals or other interven- 
tions and making such measures available in developing 
countries if they are proven to be effective. Several tri- 
als may be necessary in order to evaluate measures that 
may apply differently in various parts of the world. The 
development of a common methodological approach is 
essential in such trials as it has been for observational 
studies estimating the rate of MTCT of HIV [13,14]. 
Once evaluated and proven to be efficacious, these meas- 
ures may ultimately be associated in a comprehensive in- 
tervention to tackle the increasing problem ofperinatally 
acquired HIV infection in Af%ca and other developing 
countries. 
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Kaposi’s sarcoma (KS) is the most common AIDS- 
related neoplasm and a significant cause of morbidity and 
mortality in patients with AIDS [l]. KS is a multifocal 
disease, which may involve multiple organs. However, 
bone involvement is very rare and has been demonstrated 
in only six cases. We review the cases described in the 
literature and present a new case of an AIDS patient 
with cutaneous and pleuropulmonary KS in whom com- 
puted tomography (CT) and magnetic resonance imag- 
ing (MRI) demonstrated asymptomatic lytic bone lesions 
in the spine, not evident on bone scan or plain films, and 
which biopsy showed to be KS. 
